responses. Its approach centers on creating chimeric antigen receptor T-cell therapies inside patients, removing the need for external cell extraction and complex manufacturing processes.

The company advances a pipeline of investigational treatments, including a lead program designed to generate anti-BCMA CAR-T cells for multiple myeloma through a single infusion. This therapy is evaluated in early-stage clinical trials and is intended to target cancer cells by modifying immune cells in vivo.

Kelonia Therapeutics also engages in research collaborations to expand applications of its platform across additional disease areas, supporting the development of next-generation immuno-oncology therapies and broader genetic medicine solutions.